“Heparin:  An old drug with a new paradigm”, Jacques L, Science November 2, 1979; Vol. 206, pp: 528-533.

“Actions of heparin in the atherosclerotic process”, Engelberg H, Pharmacological Reviews 1996;
Vol. 488, #2, pp: 327-52.

“Pathogenic factors in vascular dementia and Alzheimer’s disease”, Engelberg H, Dementia in Geriatric Cognitive Disorders 2004; 18: pp: 278-298.

“Heparin inhibits skeletal muscle growth in vitro”, Kardami E, Spector D, Strohman R, Developmental Biopsy 1988;
126: pp: 19-28.

“Preventing bronchoconstriction in exercise-induced asthma with inhaled heparin”, Ahmad T, Garrigo J, Danta I, NEJM July 8,1993; Vol. #2, 329: pp: 90-95.

“Treatment of radiation-induced nervous system injury with heparin and Warfarin”, Glantz M,et al, Neurology November/1994; Vol. 44: pp: 2020-27.

“A synthetic heparin-mimicking polyanionic compound inhibits central nervous system inflammation”,
Irony-Tur-Sinai M, et al, J. of Neurol. Sci. (2003); 206; pp: 49-57.

“Heparin modulates the single channel kinetics of reconstituted AMPA receptors from rat brain”,
Sinnarajah S, et al, Synapse 1999; 31: pp: 203-209.

“Heparan sulphates up-regulate regeneration with transected sciatic nerves of adult guinea pigs”,
Chau C, Shum D, Chan Y, So K, Eur. J. of Neuroscience 1999; Vol. 11, pp: 1914-26.

“Heparin in Inflammation: Potential Therapeutic Applications beyond Anticoagulation”, Tyrell D, et al,
Advances in Pharmacology 1999; Vol. 46: pp: 151-208.

“Complications of subcutaneous low-dose heparin therapy in neurosurgical patients”, Wen D, Hall W, Surg. Neurol. December/1998; 50(6): pp: 521-5.

“Heparin-induced thrombocytopenia: what the serologists have taught us”, Kelton J, Warkentin J, J. Lab Clin. Med.; editorial Vol. 128 #4: pp: 346-48.

“Heparin inhibits induction of nitric oxide synthase by cytokines in rat brain microvascular endothelial cells”,
Bonman E, et al, Neuroscience Letters 1998; 253: pp:95-98.s